Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis

Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis

Abstract Background Guidelines show that for metastatic colorectal cancer (mCRC), a combination of three‐drug regimens, fluorouracil, leucovorin, and oxaliplatin and bevacizumab (BVZ), is one of the first‐line standard therapies. BVZ is generally well tolerated; however, it is associated with infreq...

Full description

Bibliographic Details
Main Authors: Akshit Chitkara, Nirmaljot Kaur, Aditya Desai, Devanshi Mehta, Fnu Anamika, Srawani Sarkar, Nandini Gowda, Prabhdeep Sethi, Rajat Thawani, Emerson Y. Chen
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Cancer Medicine
Subjects:
bevacizumab
colorectal neoplasms
hypertension
thromboembolism
Online Access:https://doi.org/10.1002/cam4.6662

Similar Items

Similar Items